Beam Therapeutics - BEAM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $48.80
  • Forecasted Upside: 65.03%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$29.57
▲ +1.49 (5.31%)

This chart shows the closing price for BEAM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beam Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAM

Analyst Price Target is $48.80
▲ +65.03% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $48.80, with a high forecast of $105.00 and a low forecast of $20.00. The average price target represents a 65.03% upside from the last price of $29.57.

This chart shows the closing price for BEAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in Beam Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/8/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/6/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/3/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023WedbushReiterated RatingOutperform$48.00Low
10/31/2023WedbushReiterated RatingOutperform$48.00Low
10/31/2023William BlairReiterated RatingOutperformLow
10/20/2023Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
10/20/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
10/20/2023SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00 ➝ $20.00Low
10/17/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$56.00 ➝ $32.00Low
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$56.00Low
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$56.00Low
8/9/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$46.00 ➝ $47.00Low
8/9/2023CitigroupLower TargetBuy ➝ Buy$60.00 ➝ $56.00Low
8/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$41.00 ➝ $35.00Low
8/8/2023WedbushReiterated RatingOutperform$79.00Low
5/11/2023Royal Bank of CanadaLower Target$50.00 ➝ $42.00Low
5/11/2023BarclaysLower Target$45.00 ➝ $41.00Low
3/22/2023William BlairReiterated RatingOutperformLow
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$37.00Low
3/1/2023Wells Fargo & CompanyLower TargetOverweight$125.00 ➝ $105.00Low
1/31/2023Cantor FitzgeraldInitiated CoverageOverweight$62.00Low
1/23/2023SVB LeerinkLower TargetOutperform$81.00 ➝ $77.00Low
12/20/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$61.00 ➝ $66.00Low
12/13/2022CitigroupInitiated CoverageBuy$62.00Low
11/15/2022GuggenheimLower Target$102.00N/A
11/8/2022Credit Suisse GroupLower TargetNeutral$65.00 ➝ $53.00Low
11/7/2022SVB LeerinkLower TargetOutperform$82.00 ➝ $81.00Low
8/10/2022BarclaysBoost TargetEqual Weight$38.00 ➝ $60.00Low
8/10/2022SVB LeerinkLower TargetOutperform$118.00 ➝ $113.00Low
8/1/2022WedbushReiterated RatingOutperform$100.00Low
7/18/2022BMO Capital MarketsBoost Target$41.00 ➝ $61.00Low
6/16/2022BMO Capital MarketsInitiated CoverageMarket Perform$41.00High
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$62.00High
2/28/2022WedbushLower TargetOutperform$159.00 ➝ $152.00High
1/10/2022WedbushBoost Target$148.00 ➝ $159.00High
1/10/2022SVB LeerinkBoost TargetOutperform$116.00 ➝ $121.00High
1/5/2022GuggenheimInitiated CoverageBuy$130.00High
11/9/2021SVB LeerinkLower TargetOutperform$117.00 ➝ $116.00Medium
10/19/2021SVB LeerinkInitiated CoverageOutperform$117.00High
9/24/2021Stifel NicolausInitiated CoverageBuy$85.00 ➝ $120.00Medium
9/10/2021Bank of AmericaInitiated CoverageBuy$150.00Low
6/29/2021WedbushBoost TargetOutperform$114.00 ➝ $149.00Medium
5/11/2021Redburn PartnersInitiated CoverageBuyHigh
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$85.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
2/25/2021WedbushBoost Target$42.00 ➝ $112.00High
2/16/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00Low
1/5/2021Stifel NicolausInitiated CoverageHoldN/A
10/16/2020WedbushReiterated RatingOutperform$40.00N/A
8/12/2020William BlairInitiated CoverageBuyN/A
8/5/2020William BlairReiterated RatingOutperform$33.00Medium
8/5/2020William BlairInitiated CoverageOutperform$33.00N/A
5/13/2020WedbushReiterated RatingOutperform$32.00N/A
3/2/2020WedbushReiterated RatingOutperformHigh
3/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$31.00N/A
3/2/2020WedbushInitiated CoverageOutperform ➝ Outperform$32.00 ➝ $32.00N/A
3/2/2020Jefferies Financial GroupInitiated CoverageBuy$32.00N/A
3/2/2020BarclaysInitiated CoverageOverweight$32.00N/A
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/7/2023
  • 8 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/6/2023
  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/6/2023
  • 7 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/5/2023
  • 11 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/4/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2023
  • 6 very positive mentions
  • 17 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
11/3/2023
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/3/2023

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $29.57
Low: $27.04
High: $29.61

50 Day Range

MA: $23.50
Low: $17.69
High: $30.76

52 Week Range

Now: $29.57
Low: $16.95
High: $51.60

Volume

1,133,616 shs

Average Volume

1,647,216 shs

Market Capitalization

$2.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Beam Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Beam Therapeutics in the last year: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Leerink Partnrs, Royal Bank of Canada, Sanford C. Bernstein, SVB Leerink LLC, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BEAM.

What is the current price target for Beam Therapeutics?

10 Wall Street analysts have set twelve-month price targets for Beam Therapeutics in the last year. Their average twelve-month price target is $48.80, suggesting a possible upside of 65.0%. Wells Fargo & Company has the highest price target set, predicting BEAM will reach $105.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $20.00 for Beam Therapeutics in the next year.
View the latest price targets for BEAM.

What is the current consensus analyst rating for Beam Therapeutics?

Beam Therapeutics currently has 6 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BEAM, but not buy more shares or sell existing shares.
View the latest ratings for BEAM.

What other companies compete with Beam Therapeutics?

How do I contact Beam Therapeutics' investor relations team?

Beam Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-327-8775 and its investor relations email address is inve[email protected]. The official website for Beam Therapeutics is www.beamtx.com. Learn More about contacing Beam Therapeutics investor relations.